Stemline Therapeutics Lands $33,000,000 New Round

  • Feed Type
  • Date
    1/29/2013
  • Company Name
    Stemline Therapeutics
  • Mailing Address
    1675 York Ave New York, NY 10128
  • Company Description
    Stemline Therapeutics, Inc. (NASDAQ: STML) is a clinical stage biotechnology company developing oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. Behind its lead, Stemline is developing a pipeline of small molecule and biologic compounds directed at additional cancer stem cell targets of a variety of solid and hematological cancers.
  • Website
    http://www.stemline.com
  • Transaction Type
    IPO
  • Transaction Amount
    $33,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes are on file with company statements at the SEC.
  • M&A Terms

By posting a comment, you agree to our terms and conditions.